Tempest Therapeutics (TPST)
NASDAQ:TPST
TPST Stock Chart & Stats
$1.58
$0.02(2.27%)
At close: 4:00 PM EST
$1.58
$0.02(2.27%)
Day’s Range― - ―
52-Week Range$1.50 - $12.23
Previous CloseN/A
Volume2.28M
Average Volume (3M)50.79K
Market Cap
$22.66M
Enterprise Value$9.54M
Total Cash (Recent Filing)$7.71M
Total Debt (Recent Filing)$8.14M
Price to Earnings (P/E)―
Beta1.85
Next Earnings
May 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.31
Shares Outstanding14,344,034
10 Day Avg. Volume57,939
30 Day Avg. Volume50,791
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.79
Price to Sales (P/S)0.00
P/FCF Ratio-0.44
Enterprise Value/Market Cap0.42
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-48.17
Enterprise Value/Ebitda-0.37
Forecast
1Y Price Target
$11.00Price Target Upside596.20% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-2.76
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Cash Runway And Deal BenefitsThe acquisition and transaction structure extend the company's cash runway, providing time to advance the lead program through initial clinical milestones and reducing near‑term financing pressure.
Clinical ResultsStrong early clinical responses from the lead dual‑target CAR‑T, showing complete remissions, durable disease control and a favorable safety profile, could boost confidence in the program's therapeutic potential.
Regulatory PathwayPlanned pursuit of regulatory clearance and a registrational trial for the lead CAR‑T creates a clear development route that could unlock approval and commercialization value in major markets.
Bears Say
Legacy Program DeprioritizationLegacy oncology programs have been deprioritized and will require new financing or partnerships to progress, increasing the risk that those assets stall.
Partnership And Financing DependencyProgress for deprioritized drug candidates depends heavily on external partnerships or additional financing, creating uncertainty around timelines and value realization.
Shareholder DilutionExisting shareholders lose majority ownership and face substantial dilution from the transaction, which can weaken investor sentiment and share price support.
Tempest Therapeutics News
TPST FAQ
What was Tempest Therapeutics’s price range in the past 12 months?
Tempest Therapeutics lowest stock price was $1.50 and its highest was $12.23 in the past 12 months.
What is Tempest Therapeutics’s market cap?
Tempest Therapeutics’s market cap is $22.66M.
When is Tempest Therapeutics’s upcoming earnings report date?
Tempest Therapeutics’s upcoming earnings report date is May 07, 2026 which is in 26 days.
How were Tempest Therapeutics’s earnings last quarter?
Tempest Therapeutics released its earnings results on Mar 30, 2026. The company reported -$0.31 earnings per share for the quarter, beating the consensus estimate of -$0.62 by $0.31.
Is Tempest Therapeutics overvalued?
According to Wall Street analysts Tempest Therapeutics’s price is currently Undervalued.
Does Tempest Therapeutics pay dividends?
Tempest Therapeutics does not currently pay dividends.
What is Tempest Therapeutics’s EPS estimate?
Tempest Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tempest Therapeutics have?
Tempest Therapeutics has 14,344,034 shares outstanding.
What happened to Tempest Therapeutics’s price movement after its last earnings report?
Tempest Therapeutics reported an EPS of -$0.31 in its last earnings report, beating expectations of -$0.62. Following the earnings report the stock price went down -12.139%.
Which hedge fund is a major shareholder of Tempest Therapeutics?
Currently, no hedge funds are holding shares in TPST
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Tempest Therapeutics
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.
TPST Stock 12 Month Forecast
Average Price Target
$11.00
▲(596.20% Upside)
Technical Analysis
Ownership Overview
― Insiders
1.29% Mutual Funds
1.40% Other Institutional Investors
96.24% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---